# BEFORE THE BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA

In the Matter of the Accusation Against:

# GLENCO MED INC., DBA REMEDY DRUGS, MELINA KHALAJ, PRESIDENT,

Pharmacy Permit No. PHY 42129;

and

#### MELINA ISSAKHANIAN, AKA MELINA KHALAJ,

Pharmacy Technician License No. TCH 14187;

**Respondents.** 

Agency Case No. 6951

OAH No. 2021050361

## **DECISION AND ORDER**

The attached Stipulated Settlement and Disciplinary Order is hereby adopted by the

Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on January 5, 2022.

It is so ORDERED on December 6, 2021.

BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA

Seung W. Oh, Pharm D. Board President

1	ROB BONTA Attorney General of California				
2	NANCY A. KAISER Supervising Deputy Attorney General				
3	MELISSA TYNER				
4	Deputy Attorney General State Bar No. 269649 300 So. Spring Street, Suite 1702				
5	Los Angeles, CA 90013 Telephone: (213) 269-6314				
6	Facsimile: (916) 731-2126 E-mail: Melissa.Tyner@doj.ca.gov				
7	Attorneys for Complainant				
8	RECOR				
9	BEFOR BOARD OF P	HARMACY			
10	DEPARTMENT OF CO STATE OF C				
11					
12	In the Matter of the Accusation Against:	Case No. 6951			
13	GLENCO MED INC., DBA REMEDY DRUGS, MELINA KHALAJ, PRESIDENT	OAH No. 2021050361			
14	1700 W. Glenoaks Blvd. Glendale, CA 91201	STIPULATED SURRENDER OF LICENSE AND ORDER OF PHARMACY			
15	Pharmacy Permit No. PHY 42129,	TECHNICIAN MELINA ISSAKHANIAN, AKA MELINA KHALAJ ONLY			
16	and				
17	MELINA ISSAKHANIAN, AKA MELINA				
18	KHALAJ 1812 Foothill Drive				
19	Glendale, CA 91201				
20	Pharmacy Technician License No. TCH 14187,				
21	Respondents.				
22					
23					
24	IT IS HEREBY STIPULATED AND AGR	EED by and between the parties to the above-			
25	entitled proceedings that the following matters are	-			
26	PAR				
27		Executive Officer of the Board of Pharmacy			
28					
	(Board). She brought this action solely in her official capacity and is represented in this matter by 1				
		ed Surrender of License (Issakhanian) (Case No. 6951)			

Rob Bonta, Attorney General of the State of California, by Melissa Tyner, Deputy Attorney 1 2 General. 2. Melina Issakhanian, aka Melina Khalaj (Respondent) is represented in this proceeding 3 by attorney Herb Weinburg, whose address is: 1990 S Bundy Drive, Suite 777, Los Angeles, CA 4 5 90025. 3. On or about October 24, 1994, the Board of Pharmacy issued Pharmacy Technician 6 Registration Number TCH 14187 to Melina Issakhanian, aka Melina Khalaj. The Pharmacy 7 Technician Registration expired on July 31, 2008, and has not been renewed. 8 9 JURISDICTION 4. Accusation No. 6951 was filed before the Board, and is currently pending against 10 Respondent. The Accusation and all other statutorily required documents were properly served 11 on Respondent on March 16, 2021. Respondent timely filed her Notice of Defense contesting the 12 Accusation. A copy of Accusation No. 6951 is attached as Exhibit A and incorporated by 13 14 reference. **ADVISEMENT AND WAIVERS** 15 5. Respondent has carefully read, fully discussed with counsel, and understands the 16 charges and allegations in Accusation No. 6951. Respondent also has carefully read, fully 17 discussed with counsel, and understands the effects of this Stipulated Surrender of License and 18 Order. 19 6. Respondent is fully aware of her legal rights in this matter, including the right to a 20 21 hearing on the charges and allegations in the Accusation; the right to confront and cross-examine the witnesses against them; the right to present evidence and to testify on her own behalf; the 22 right to the issuance of subpoenas to compel the attendance of witnesses and the production of 23 documents; the right to reconsideration and court review of an adverse decision; and all other 24 rights accorded by the California Administrative Procedure Act and other applicable laws. 25 7. Respondent voluntarily, knowingly, and intelligently waives and gives up each and 26 every right set forth above. 27 28

1	<u>CULPABILITY</u>
2	8. Respondent understands that the charges and allegations in Accusation No. 6951, if
3	proven at a hearing, constitute cause for imposing discipline upon her Pharmacy Technician
4	License.
5	9. For the purpose of resolving the Accusation without the expense and uncertainty of
6	further proceedings, Respondent agrees that, at a hearing, Complainant could establish a factual
7	basis for the charges in the Accusation and that those charges constitute cause for discipline.
8	Respondent hereby gives up their right to contest that cause for discipline exists based on those
9	charges.
10	10. Respondent understands that by signing this stipulation Respondent enables the Board
11	to issue an order accepting the surrender of her Pharmacy Technician License without further
12	process.
13	<u>CONTINGENCY</u>
14	11. This stipulation shall be subject to approval by the Board. Respondent understands
15	and agrees that counsel for Complainant and the staff of the Board may communicate directly
16	with the Board regarding this stipulation and surrender, without notice to or participation by
17	Respondent or her counsel. By signing the stipulation, Respondent understands and agrees that
18	they may not withdraw her agreement or seek to rescind the stipulation prior to the time the Board
19	considers and acts upon it. If the Board fails to adopt this stipulation as its Decision and Order,
20	the Stipulated Surrender and Disciplinary Order shall be of no force or effect, except for this
21	paragraph, it shall be inadmissible in any legal action between the parties, and the Board shall not
22	be disqualified from further action by having considered this matter.
23	12. The parties understand and agree that Portable Document Format (PDF) and facsimile
24	copies of this Stipulated Surrender of License and Order, including PDF and facsimile signatures
25	thereto, shall have the same force and effect as the originals.
26	13. This Stipulated Surrender of License and Order is intended by the parties to be an
27	integrated writing representing the complete, final, and exclusive embodiment of their agreement.
28	It supersedes any and all prior or contemporaneous agreements, understandings, discussions,
	3
	$\mathbf{C}_{4} = \mathbf{C}_{4} + \mathbf{C}_{4} $

## Stipulated Surrender of License (Issakhanian) (Case No. 6951)

1	negotiations, and commitments (written or oral). This Stipulated Surrender of License and Order
2	may not be altered, amended, modified, supplemented, or otherwise changed except by a writing
3	executed by an authorized representative of each of the parties.
4	14. In consideration of the foregoing admissions and stipulations, the parties agree that
5	the Board may, without further notice or formal proceeding, issue and enter the following Order:
6	<u>ORDER</u>
7	IT IS HEREBY ORDERED that Pharmacist Technician License No. TCH 14187, issued to
8	Respondent Melina Issakhanian, Aka Melina Khalaj, is surrendered and accepted by the Board.
9	Respondent(s) understand and acknowledge that for purposes of Business and Professions Code
10	section 4307, this stipulated surrender is the same as a revocation.
11	1. Respondent shall lose all rights and privileges as a pharmacy technician in California
12	as of the effective date of the Board's Decision and Order.
13	2. Respondent shall cause to be delivered to the Board her pocket license and, if one was
14	issued, her wall certificate on or before the effective date of the Decision and Order.
15	3. If Respondent ever files an application for licensure or a petition for reinstatement in
16	the State of California, the Board shall treat it as a new application for licensure. Respondent
17	must comply with all the laws, regulations and procedures for reinstatement of a revoked or
18	surrendered license in effect at the time the petition is filed, and all of the charges and allegations
19	contained in Accusation No. 6951 shall be deemed to be true, correct and admitted by Respondent
20	when the Board determines whether to grant or deny the application. Respondent is required to
21	report this surrender as disciplinary action. Respondent may not apply for any license, permit, or
22	registration from the Board for three years from the effective date of this decision.
23	4. Respondent shall pay the agency its costs of investigation and enforcement in the
24	amount of \$5,000.00 prior to issuance of a new or reinstated license.
25	ACCEPTANCE
26	I have carefully read the above Stipulated Surrender of License and Order and have fully
27	discussed it with my attorney Herb Weinberg. I understand the stipulation and the effect it will
28	have on my Pharmacy Technician License. I enter into this Stipulated Surrender of License and
	4
	Stipulated Surrender of License (Issakhanian) (Case No. 6951)

1	Order voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order
2	of the Board of Pharmacy.
3	
4	DATED:
5 6	GLENCO MED INC., DBA REMEDY DRUGS, MELINA KHALAJ, PRESIDENT Respondent
7	I have read and fully discussed with Respondent Glenco Med Inc., dba Remedy Drugs,
	Melina Khalaj, President the terms and conditions and other matters contained in this Stipulated
8	Surrender of License and Order. I approve its form and content.
9	DATED:
10	HERB WEINBERG
11	Attorney for Respondent
12	<u>ENDORSEMENT</u>
13	The foregoing Stipulated Surrender of License and Order is hereby respectfully submitted
14	for consideration by the Board of Pharmacy of the Department of Consumer Affairs.
15 16	DATED: Respectfully submitted,
10	ROB BONTA Attornov Concrel of Colifornia
	Attorney General of California NANCY A. KAISER
18	Supervising Deputy Attorney General
19	
20	MELISSA TYNER Deputy Attorney General
21	Attorneys for Complainant
22	
23	
24	LA2020600819 Tech Stip - Glenco.docx
25	
26	
27	
28	
	5
	Stinulated Surrender of License (Issakhanian) (Case No. 6951)

Stipulated Surrender of License (Issakhanian) (Case No. 6951)

Order voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order 1 of the Board of Pharmacy. 2 3 DATED: 4 GLENCO MED INC., DBA REMEDY 5 DRUGS. MELINA KHALAJ, PRESIDENT Respondent 6 I have read and fully discussed with Respondent Glenco Med Inc., dba Remedy Drugs, 7 Melina Khalaj, President the terms and conditions and other matters contained in this Stipulated 8 Surrender of License and Order. I approve its form and conten 9 112 DATED: 10 IIERB A VEINBERG Attorie for Respondent 11 12 ENDORSEMENT 13 The foregoing Stipulated Surrender of License and Order is hereby respectfully submitted 14 for consideration by the Board of Pharmacy of the Department of Consumer Affairs. 15 DATED: 11/8/21 Respectfully submitted, 16 ROB BONTA 17 Attomey General of California NANCY A. KAISER 18 Supervising Deputy Attorney General 19 20 MELISSA TYNER Deputy Attorney General 21 Attorneys for Complainant 22 23 LA2020600819 24 Tech Stip - Glenco.doex 25 26 27 28 5

Stipulated Surrender of License (Issakhanian) (Case No. 6951)

#### Exhibit A

Accusation No. 6951

1	ROB BONTA	
2	Attorney General of California NANCY KAISER	
3	Supervising Deputy Attorney General MELISSA TYNER	
4	Deputy Attorney General State Bar No. 269649	
5	300 So. Spring Street, Suite 1702 Los Angeles, CA 90013	
6	Telephone: (213) 269-6314 Facsimile: (916) 731-2126	
7	E-mail: Melissa.Tyner@doj.ca.gov Attorneys for Complainant	
8		
9	BEFOR BOARD OF I	
10	DEPARTMENT OF C STATE OF C	
11		
12	In the Matter of the Accusation Against:	Case No. 6951
13	GLENCO MED INC., DBA REMEDY	
14 15	DRUGS, MELINA KHALAJ, PRESIDENT 1700 W. Glenoaks Blvd. Glendale, CA 91201	FIRST AMENDED ACCUSATION
16	Pharmacy Permit No. PHY 42129,	
17	and	
18	MELINA ISSAKHANIAN, AKA MELINA	
19	KHALAJ 1812 Foothill Drive Glendale, CA 91201	
20	Pharmacy Technician License No. TCH	
21	14187,	
22	Respondents.	
23		
24	D 4 D/	
25	PAR	
26		s this Accusation solely in her official capacity
27	as the Executive Officer of the Board of Pharmac	y, Department of Consumer Affairs.
28		1
		RUGS, MELINA KHALAJ, PRESIDENT, and MELINA MKHANIAN, AKA MELINA KHALAJ) ACCUSATION

1	2. On or about September 8, 2003, the Board of Pharmacy issued Pharmacy Permit			
2	Number PHY 42129 to Glenco Med Inc., dba Remedy Drugs, Melina Khalaj, President			
3	(Respondent Pharmacy). The Pharmacy Permit was in full force and effect at all times relevant to			
4	the charges brought herein and will expire on September 1, 2021, unless renewed.			
5	3. On or about October 24, 1994, the Board of Pharmacy issued Pharmacy Technician			
6	Registration Number TCH 14187 to Melina Issakhanian, aka Melina Khalaj (Respondent			
7	Issakhanian). The Pharmacy Technician Registration expired on July 31, 2008, and has not been			
8	renewed.			
9	JURISDICTION			
10	4. This Accusation is brought before the Board of Pharmacy (Board), Department of			
11	Consumer Affairs, under the authority of the following laws. All section references are to the			
12	Business and Professions Code (Code) unless otherwise indicated.			
13	5. Section 4011 of the Code provides that the Board shall administer and enforce both			
14	the Pharmacy Law [Bus. & Prof. Code, § 4000 et seq.] and the Uniform Controlled Substances			
15	Act [Health and Safety Code, § 11000 et seq.].			
16	6. Section 4300 states, in pertinent part, that "[e]very license issued may be suspended			
17	or revoked."			
18	7. Section 4300.1 of the Code states:			
19	"The expiration, cancellation, forfeiture, or suspension of a board-issued license by			
20	operation of law or by order or decision of the board or a court of law, the placement of a license			
21	on a retired status, or the voluntary surrender of a license by a licensee shall not deprive the board			
22	of jurisdiction to commence or proceed with any investigation of, or action or disciplinary			
23	proceeding against, the licensee or to render a decision suspending or revoking the license."			
24	STATUTORY PROVISIONS			
25	8. Code section 4059, subdivision (a), states:			
26	"(a) A person may not furnish any dangerous drug, except upon the prescription of a			
27	physician, dentist, podiatrist, optometrist, veterinarian, or naturopathic doctor pursuant to Section			
28	3640.7. A person may not furnish any dangerous device, except upon the prescription of a			
	2			
	(GLENCO MED INC., DBA REMEDY DRUGS, MELINA KHALAJ, PRESIDENT, and MELINA ISSAKHANIAN, AKA MELINA KHALAJ) ACCUSATION			

physician, dentist, podiatrist, optometrist, veterinarian, or naturopathic doctor pursuant to Section 3640.7.

4

5

6

7

1

2

3

9. Code section 4063 states:

"No prescription for any dangerous drug or dangerous device may be refilled except upon authorization of the prescriber. The authorization may be given orally or at the time of giving the original prescription. No prescription for any dangerous drug that is a controlled substance may be designated refillable as needed."

8

10. Code section 4081, subdivision (a), states:

"(a) All records of manufacture and of sale, acquisition, receipt, shipment, or disposition of 10 dangerous drugs or dangerous devices shall be at all times during business hours open to 11 inspection by authorized officers of the law, and shall be preserved for at least three years from 12 the date of making. A current inventory shall be kept by every manufacturer, wholesaler, third-13 14 party logistics provider, pharmacy, veterinary food-animal drug retailer, outsourcing facility, physician, dentist, podiatrist, veterinarian, laboratory, licensed correctional clinic, as defined in 15 Section 4187, clinic, hospital, institution, or establishment holding a currently valid and 16 unrevoked certificate, license, permit, registration, or exemption under Division 2 (commencing 17 with Section 1200) of the Health and Safety Code or under Part 4 (commencing with Section 18 16000) of Division 9 of the Welfare and Institutions Code who maintains a stock of dangerous 19 drugs or dangerous devices." 20

21

11. Code section 4105 states, in pertinent part:

"(a) All records or other documentation of the acquisition and disposition of dangerous
drugs and dangerous devices by any entity licensed by the board shall be retained on the licensed
premises in a readily retrievable form.

25

26 (c) The records required by this section shall be retained on the licensed premises for a
27 period of three years from the date of making."

28

///

1	12. Code section 4301 states, in pertinent part:
2	"Section 4301 of the Code states:
3	The board shall take action against any holder of a license who is guilty of unprofessional
4	conduct or whose license has been issued by mistake. Unprofessional conduct shall include, but is
5	not limited to, any of the following:
6	
7	(j) The violation of any of the statutes of this state, of any other state, or of the United
8	States regulating controlled substances and dangerous drugs.
9	
10	(o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the
11	violation of or conspiring to violate any provision or term of this chapter or of the applicable
12	federal and state laws and regulations governing pharmacy, including regulations established by
13	the board or by any other state or federal regulatory agency.
14	"
15	13. Section 4307, subdivision (a), of the Code states:
16	"Any person who has been denied a license or whose license has been revoked or is under
17	suspension, or who has failed to renew his or her license while it was under suspension, or who
18	has been a manager, administrator, owner member, officer, director, associate, or partner of any
19	partnership, corporation, firm, or association whose application for a license has been denied or
20	revoked, is under suspension or has been placed on probation, and while acting as the manger,
21	administrator, owner, member, officer, director, associate, or partner had knowledge or
22	knowingly participated in any conduct for which the license was denied, revoked, suspended, or
23	placed on probation, shall be prohibited from serving as a manger, administrator, owner, member,
24	officer, director, associate, or partner of a licensee as follows:
25	(1) Where a probationary license is issued or where an existing license is placed on
26	probation, this prohibition shall remain in effect for a period not to exceed five years.
27	(2) Where the license is denied or revoked, the prohibition shall continue until the license is
28	issued or reinstated."
	(GLENCO MED INC., DBA REMEDY DRUGS, MELINA KHALAJ, PRESIDENT, and MELINA ISSAKHANIAN, AKA MELINA KHALAJ) ACCUSATION

1	REGULATORY PROVISIONS
2	14. California Code of Regulations, title 16, section 1716 states:
3	"Pharmacists shall not deviate from the requirements of a prescription except upon the prior
4	consent of the prescriber or to select the drug product in accordance with Section 4073 of the
5	Business and Professions Code.
6	Nothing in this regulation is intended to prohibit a pharmacist from exercising commonly-
7	accepted pharmaceutical practice in the compounding or dispensing of a prescription."
8	15. California Code of Regulations, title 16, section 1718 states:
9	"Current Inventory" as used in Sections 4081 and 4332 of the Business and Professions
10	Code shall be considered to include complete accountability for all dangerous drugs handled by
11	every licensee enumerated in Sections 4081 and 4332.
12	The controlled substances inventories required by Title 21, CFR, Section 1304 shall be
13	available for inspection upon request for at least 3 years after the date of the inventory."
14	COST RECOVERY
15	16. Section 125.3 provides that the Board may request the administrative law judge to
16	direct a licentiate found to have committed a violation or violations of the licensing act to pay a
17	sum not to exceed the reasonable costs of the investigation and enforcement of the case, with
18	failure of the licentiate to comply subjecting the license to not being renewed or reinstated. If a
19	case settles, recovery of investigation and enforcement costs may be included in a stipulated
20	settlement.
21	DANGEROUS DRUGS
22	17. Section 4022 of the Code states:
23	"Dangerous drug' or 'dangerous device' means any drug or device unsafe for self-use in
24	humans or animals, and includes the following:
25	(a) Any drug that bears the legend: 'Caution: federal law prohibits dispensing without
26	prescription,' 'Rx only,' or words of similar import.
27	///
28	///
	5
	(GLENCO MED INC., DBA REMEDY DRUGS, MELINA KHALAJ, PRESIDENT, and MELINA ISSAKHANIAN, AKA MELINA KHALAJ) ACCUSATION

1	(b) Any device that bears the statement: 'Caution: federal law restricts this device to sale by
2	or on the order of a, ' 'Rx only,' or words of similar import, the blank to be filled in
3	with the designation of the practitioner licensed to use or order use of the device.
4	(c) Any other drug or device that by federal or state law can be lawfully dispensed only on
5	prescription or furnished pursuant to Section 4006."
6	18. "Colcrys" is a brand name for colchicine and is a dangerous drug within the meaning
7	of Business and Professions Code section 4022.
8	19. "Dexilant" is a brand name for dexlansoprazole and is a dangerous drug within the
9	meaning of Business and Professions Code section 4022.
10	20. "Linzess" is a brand name for linaclotide and is a dangerous drug within the meaning
11	of Business and Professions Code section 4022.
12	21. "Restasis" is a brand name for cyclosporine ophthalmic emulsion and is a dangerous
13	drug within the meaning of Business and Professions Code section 4022.
14	22. "Voltaren Gel" is a brand name for diclofenac and is a dangerous drug within the
15	meaning of Business and Professions Code section 4022.
16	23. "Zetia" is a brand name for ezetimibe and is a dangerous drug within the meaning of
17	Business and Professions Code section 4022.
18	FACTUAL ALLEGATIONS: DRUG OVERAGES
19	24. On or about September 14, 2018, the Board received a complaint from Qlarant, as a
20	Medicare Drug Integrity Contractor (MEDIC), operating the National Benefit Integrity (NBI)
21	MEDIC. The NBI MEDIC is contracted by the Centers for Medicare & Medicaid Services
22	(CMS) to conduct investigations into fraud in the Medicare Part C and D programs. NBI MEDIC
23	received complaints from other health care plans and pharmacy benefit managers regarding the
24	discrepancies they had identified when they conducted audits on Respondent Pharmacy.
25	25. On or about November 11, 2019, a Board inspector visited Respondent Pharmacy to
26	conduct an inspection and obtain records. The Board's inspector also obtained records from
27	Respondent Pharmacy's wholesalers. Based on the evidence collected, the Board inspector
28	performed an audit for the period between November 11, 2017 and November 11, 2019.
	6
	(GLENCO MED INC., DBA REMEDY DRUGS, MELINA KHALAJ, PRESIDENT, and MELINA ISSAKHANIAN, AKA MELINA KHALAJ) ACCUSATION

26. The Bo	ard audit indicated	a negative varia	nce of the following m	edications indic
Respondent Pharmacy sold (dispensed) a greater amount of medication than it purchased: Ud				
Restasis 0.05% Eye	e Emlsn 30 Vials an	d 60 Vials, Rest	asis Multidose 0.05%	Drp, Dexilant 6
Voltaren 1% Gel, a	nd Zetia 10mg Tab.			
27. The Bo	ard's inspector iden	tified the follow	ving dollar amounts Re	spondent Pharr
was reimbursed for	the identified overa	5		
Medication	Units	Variance	Price per Unit Paid by Insurance	Total Dollar Amounts Pa by Insuranc for the Variances
Ud Restasis	Vials (30 vials in	-2,520	\$9.21	\$(23,207.96)
.05% Eye Emlsn	a box)			
30				
Ud Restasis	Vials (60 vials in	-22,500	\$8.94	\$(201,179.39
.05% Eye Emlsn	a box)			
60				
Restasis	Multidose	-115	\$527.31	\$(60,640.12)
Multidose .05%	dropper (1			
DRP	dropper)			
Dexilant 60mg	Capsules	-11,490	\$9.21	\$(105,817.27
Voltaren 1% Gel	Grams (100	-882	\$52.85	\$(46,613.70)
	grams per box)			
Zetia 10mg Tab	Tablet	-750	\$9.92	\$(7,443.49)
Grand Total				\$(444,901.93
///				
///				
///				
///				

1	FIRST CAUSE FOR DISCIPLINE
2	(Failure to Maintain Accurate Records of Acquisition and Disposition)
3	28. Respondent Pharmacy and Respondent Issakhanian are subject to disciplinary action
4	under Code section 4301, subdivision (o), in conjunction with Code sections 4081 and 4105, and
5	California Code of Regulations section 1718. Specifically, an audit for the period between
6	November 11, 2017 and November 11, 2019 of Respondent Pharmacy revealed an overage (sold
7	more than purchased) of Ud Restasis .05% Eye Emlsn 30 Vials and 60 Vials, Restasis Multidose
8	.05% Drp, Dexilant 60mg, Voltaren 1% Gel and Zetia 10mg Tab. Complainant refers to, and by
9	this reference incorporates, the allegations set forth above in paragraphs 24 through 27, inclusive,
10	as though set forth fully herein.
11	FACTUAL ALLEGATIONS: FURNISHING DANGEROUS DRUGS WITHOUT A
12	PRESCRIPTION
13	29. On August 22, 2019, the Board received a complaint from Humana regarding
14	Respondent Pharmacy. The complaint alleged Respondent Pharmacy had billed several
15	prescriptions which had the wrong medication, prescriber, quantity, day supply and had dispensed
16	unauthorized prescriptions.
17	30. On November 11, 2019, the Board conducted an inspection of Respondent Pharmacy.
18	The Board's inspector reviewed prescription profile records for AY and ZP between November
19	11, 2017 and November 11, 2019, as well as its Drug Utilization Report (DUR) for the same
20	period.
21	31. Using the DUR, the Board's inspector contacted the prescribing physicians and
22	confirmed that prescription numbers 6809410 (for Linzess 145mcg, quantity of 270 capsules),
23	6811757 (Colcrys 0.6mg, quantity of 120), and 6824285 (Dexilant 60mg, quantity of 210) were
24	unauthorized. Further, using the DUR, the Board's inspector determined the dollar amount
25	Respondent Pharmacy was billed for the unauthorized prescriptions, which amounted to
26	\$7,598.40.
27	///
28	///
	8
	(GLENCO MED INC., DBA REMEDY DRUGS, MELINA KHALAJ, PRESIDENT, and MELINA ISSAKHANIAN, AKA MELINA KHALAJ) ACCUSATION

1	SECOND CAUSE FOR DISCIPLINE		
2	(Furnishing Dangerous Drugs without a Prescription)		
3	32. Respondent Pharmacy is subject to disciplinary action under Code section 4301,		
4	subdivision (o), in conjunction with Code sections 4059, subdivision (a), 4063 and California		
5	Code of Regulations, title 16, section 1716. Specifically, during the course of the Board's		
6	investigation, it was determined that Respondents had dispensed without prescriber's		
7	authorization a prescription (number 6809410) for Linzess 145mcg (quantity of 270 capsules), a		
8	prescription (number 6811757) for Colcrys 0.6mg (quantity of 120), and a prescription (number		
9	6824285) for Dexilant 60mg (quantity of 210). Complainant refers to, and by this reference		
10	incorporates, the allegations set forth above in paragraphs 29 through 31, inclusive, as though set		
11	forth fully herein.		
12	OTHER MATTERS		
13	33. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number		
14	PHY 42129 issued to Respondent Glenco Med Inc., dba Remedy Drugs, Glenco Med Inc. shall be		
15	prohibited from serving as manager, administrator, owner, members, officer, director, associate,		
16	or partner of a licensee for five years if Pharmacy Permit Number PHY 42129 is placed on		
17	probation or until Pharmacy Permit Number PHY 42129 is reinstated if it is revoked.		
18	34. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number		
19	PHY 42129 issued to Respondent Glenco Med Inc., dba Remedy Drugs for conduct that occurred		
20	while Melina Khalaj was a manager, administrator, owner, member, officer, director, associate,		
21	partner or other person with management or control of Respondent Glenco Med Inc., dba Remedy		
22	Drugs and had knowledge of or knowingly participated in any conduct for which the license was		
23	disciplined, Melina Khalaj shall be prohibited from serving as manager, administrator, owner,		
24	members, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit		
25	Number PHY 42129 is placed on probation or until Pharmacy Permit Number PHY 42129 is		
26	reinstated if it is revoked.		
27	35. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number		
28	PHY 42129 issued to Respondent Glenco Med Inc., dba Remedy Drugs for conduct that occurred 9		
	GLENCO MED INC., DBA REMEDY DRUGS, MELINA KHALAJ, PRESIDENT, and MELINA ISSAKHANIAN, AKA MELINA KHALAJ) ACCUSATION		

1	while Respondent Issakhanian was a manager, administrator, owner, member, officer, director,
2	associate, partner or other person with management or control of Respondent Glenco Med Inc.,
3	dba Remedy Drugs and had knowledge of or knowingly participated in any conduct for which the
4	license was disciplined, Respondent Issakhanian shall be prohibited from serving as manager,
5	administrator, owner, members, officer, director, associate, or partner of a licensee for five years
6	if Pharmacy Permit Number PHY 42129 is placed on probation or until Pharmacy Permit Number
7	PHY 42129 is reinstated if it is revoked.
8	<u>PRAYER</u>
9	WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,
10	and that following the hearing, the Board of Pharmacy issue a decision:
11	1. Revoking or suspending Pharmacy Permit Number PHY 42129, issued to Glenco
12	Med Inc., dba Remedy Drugs, Melina Khalaj, President;
13	2. Revoking or suspending Pharmacy Technician Registration Number TCH 14187,
14	issued to Melina Issakhanian;
15	3. Prohibiting Glenco Med Inc. from serving as a manager, administrator, owner,
16	member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit
17	Number PHY 42129 is placed on probation or until Pharmacy Permit Number PHY 42129 is
18	reinstated if Pharmacy Permit Number PHY 42129 issued to Glenco Med Inc. is revoked;
19	4. Prohibiting Melina Khalaj from serving as a manager, administrator, owner, member,
20	officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number
21	PHY 42129 is placed on probation or until Pharmacy Permit Number PHY 42129 is reinstated if
22	Pharmacy Permit Number PHY 42129 issued to Glenco Med Inc. is revoked;
23	5. Ordering Remedy Drugs and Melina Issakhanian to pay the Board of Pharmacy the
24	reasonable costs of the investigation and enforcement of this case, pursuant to Business and
25	Professions Code section 125.3; and,
26	///
27	///
28	///
	10
	(GLENCO MED INC., DBA REMEDY DRUGS, MELINA KHALAJ, PRESIDENT, and MELINA ISSAKHANIAN, AKA MELINA KHALAJ) ACCUSATION

3     DATED:     10/11/2021     Signature on File       4     ANNE SODERGREN       Executive Officer     Board of Pharmacy       Department of Consumer Affairs     State of California       7     Complainant       9     Accusation - KJS.docx       10     Accusation - KJS.docx       11     Accusation - KJS.docx       12     Accusation - KJS.docx	
JATED:      ANNE SODERGREN         Executive Officer       Board of Pharmacy         Department of Consumer Affairs       State of California         Complainant       Complainant         10       Accusation - KJS.doex         11       Accusation - KJS.doex         12       Accusation - KJS.doex         13       Accusation - KJS.doex         14       Accusation - KJS.doex         15       Accusation - KJS.doex         16       Accusation - KJS.doex         17       Accusation - KJS.doex         18       Accusation - KJS.doex         19       Accusation - KJS.doex         20       Accusation - KJS.doex         21       Accusation - KJS.doex         22       Accusation - KJS.doex	
4       Executive Officer Board of Pharmacy Department of Consumer Affairs State of California <i>Complainant</i> 7       I.A2020600819         4       Accusation - KJS.docx         10       I.A2020600819         11       I.A2020600819         12       I.A2020600819         13       I.A2020600819         14       I.A2020600819         15       I.A2020600819         16       I.A2020600819         17       I.A2020600819         18       I.A2020600819         19       I.A2020600819         20       I.A2020600819         21       I.A2020600819         22       I.A2020600819         23       I.A2020600819         24       I.A2020600819	_
6       Complainant         7       LA2020600819         Accusation - KJS.docx         10         11         12         13         14         15         16         17         18         19         20         21         22         23         24         25	
6       Complainant         7       LA2020600819         Accusation - KJS.docx         10         11         12         13         14         15         16         17         18         19         20         21         22         23         24         25	
8       LA2020600819         9       Accusation - KJS.docx         10	
PACUSATION - KJS.docx       10       11       12       13       14       15       16       17       18       19       20       21       22       23       24       25	
9         10         11         12         13         14         15         16         17         18         19         20         21         22         23         24         25	
11         12         13         14         15         16         17         18         19         20         21         22         23         24         25	
12         13         14         15         16         17         18         19         20         21         22         23         24         25	
13         14         15         16         17         18         19         20         21         22         23         24         25	
14         15         16         17         18         19         20         21         22         23         24         25	
15         16         17         18         19         20         21         22         23         24         25	
16         17         18         19         20         21         22         23         24         25	
17         18         19         20         21         22         23         24         25	
18         19         20         21         22         23         24         25	
19         20         21         22         23         24         25	
20 21 22 23 24 25	
21         22         23         24         25	
22 23 24 25	
23 24 25	
24 25	
25	
26	
27	
28	
11 (GLENCO MED INC., DBA REMEDY DRUGS, MELINA KHALAJ, PRESIDENT, and ISSAKHANIAN, AKA MELINA KHALAJ) ACCU	d MELINA